Becton Dickinson and Co. (BDX) delivered a solid quarter on Monday, but Wall Street wasn't in the mood to celebrate. The medical technology company beat earnings expectations for its first quarter of fiscal 2026, posting adjusted earnings of $2.91 per share against a consensus estimate of $2.81. Revenue came in at $5.25 billion, comfortably ahead of the $5.15 billion analysts were expecting.

So why did shares crater more than 17%? The answer lies in what comes next.

A Major Guidance Reduction

Becton Dickinson provided fiscal 2026 guidance for its newly configured business—reflecting the separation of its Biosciences and Diagnostic Solutions divisions and the combination with Waters Corporation (WAT). The outlook wasn't pretty. The company slashed its full-year adjusted earnings forecast from $14.75-$15.05 per share down to $12.35-$12.65 per share. That's well below the consensus of $14.72.

For the second quarter specifically, management expects adjusted earnings between $2.72 and $2.82 per share.

Analysts React: The Transition Year

RBC Capital Markets wasted no time adjusting its outlook, cutting its price target from $210 to $172. The firm's reasoning? "We see FY26 as a transition year." Analyst Shagun Singh pointed to the dynamics of the Waters deal and modeled organic revenue growth of 2.5% in fiscal 2026 and 2.4% in fiscal 2027, with EPS growth of 6.0% and 6.9% in those respective years.

Singh noted that despite the disappointing second-quarter guide, the fiscal 2026 outlook was maintained because business trends are playing out as expected. The company is navigating headwinds of roughly 250 basis points from three key areas: China, vaccines, and Alaris. "We are encouraged by the Q1 print even as BD navigates several business headwinds," Singh said, maintaining a Sector Perform rating.

There's a silver lining buried in the report: about 90% of Becton Dickinson's business is currently delivering mid-single-digit growth. The challenge is proving that the overall growth recovery can reach those mid-single digits across the board.

On the M&A front, RBC highlighted that management is focused on tuck-in acquisitions rather than transformational deals, with a robust pipeline centered on accretive opportunities.

Wall Street Downgrades Pile Up

RBC wasn't alone in recalibrating expectations. Wells Fargo maintained an Equal-Weight rating but lowered its price target from $184 to $157. Piper Sandler kept its Neutral rating while cutting its target from $205 to $170. Citigroup was the most optimistic, maintaining a Buy rating but trimming its price target from $233 to $232.

Becton Dickinson shares were trading down 17.44% at $171.23 at the time of publication Tuesday.